Article
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Oncology research and treatment - 1 Jan 2017
Igawa Satoshi, Ryuge Shiichiro, Ichinoe Masaaki, Nakashima Hiroyasu, Otani Sakiko, Nakahara Yoshiro, Fukui Tomoya, Sasaki Jiichiro, Kubota Masaru, Katagiri Masato, Murakumo Yoshiki, Satoh Yukitoshi, Sato Yuichi, Masuda Noriyuki
Abstract excerpt
BACKGROUND: It is unclear whether there is a difference in the efficacy of treatment by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) between patients with postoperative recurrent non-small-cell lung cancer (NSCLC) and those with stage IV NSCLC harboring EGFR mutations. PATIENTS AND METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.